Colorectal cancer exhibits oxaliplatin resistance mediated by Fusobacterium nucleatum via the E-cadherin/β-catenin/TCF4/GPX4 axis, and the KIF20A/NUAK1/PP1β/GPX4 pathway may further support this resistance[61,62]. This evidence concerns the gene GPX4 and colorectal cancer.